Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cross-omics analysis revealed gut microbiome-related metabolic pathways underlying atherosclerosis development after antibiotics treatment.

Molecular metabolism·2020
Same author

Electrothermal patches driving the transdermal delivery of insulin.

Nanoscale horizons·2020
Same author

Incretin combination therapy for the treatment of non-alcoholic steatohepatitis.

Diabetes, obesity & metabolism·2020
Same author

Pirfenidone Is an Agonistic Ligand for PPARα and Improves NASH by Activation of SIRT1/LKB1/pAMPK.

Hepatology communications·2020
Same author

Microbiome Modulation of the Host Adaptive Immunity through Bile Acid Modification.

Cell metabolism·2020
Same author

Analysis of the association of MPO and MMP-9 with stroke severity and outcome: Cohort study.

Neurology·2020

Related Experiment Videos

Bile acid sequestrants: glucose-lowering mechanisms.

Janne Prawitt1, Bart Staels

  • 1University of Lille Nord de France, Lille, France.

Metabolic Syndrome and Related Disorders
|October 28, 2010
PubMed
Summary

Bile acids regulate metabolism by signaling through FXR and TGR5. Bile acid sequestrants lower cholesterol and improve glycemic control in diabetic patients by removing bile acids.

Area of Science:

  • Metabolic signaling
  • Endocrinology
  • Gastroenterology

Background:

  • Bile acids function as signaling molecules regulating metabolic homeostasis.
  • They interact with nuclear (FXR) and membrane (TGR5) receptors.
  • Bile acids influence lipid, glucose, and energy metabolism.

Purpose of the Study:

  • To review signaling pathways in bile acid-mediated glucose regulation.
  • To summarize current understanding of glucose-lowering mechanisms of bile acid sequestrants.

Main Methods:

  • Literature review of bile acid signaling and sequestrant mechanisms.
  • Analysis of pathways involving farnesoid X receptor (FXR) and TGR5.
  • Examination of clinical data on sequestrants in dyslipidemia and diabetes.

Related Experiment Videos

Main Results:

  • Bile acid sequestrants effectively reduce plasma cholesterol in dyslipidemia.
  • Sequestrants demonstrate glucose-lowering effects, aiding glycemic control in diabetic patients.
  • These effects are linked to the modulation of bile acid signaling pathways.

Conclusions:

  • Bile acids are crucial regulators of metabolic and glycemic control.
  • Bile acid sequestrants offer a therapeutic strategy for managing dyslipidemia and hyperglycemia.
  • Further research into these mechanisms can optimize therapeutic applications.